Dirk G. Brockstedt

Rapt Therapeutics (United States) — United States

Immunology and Microbiology · Life Sciences

35h-index7.7kcitations195works1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(65), Cancer Research and Treatments(61), Cancer Immunotherapy and Biomarkers(51), Pancreatic and Hepatic Oncology Research(51), Listeria monocytogenes in Food Safety(23)

Publications195 total

Discovery and Characterization of Zelnecirnon (RPT193), a Potent and Selective CCR4 Antagonist for Allergic Disorders
Journal of Medicinal Chemistry·2026
Abstract CT226: Phase 2 study of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with head and neck squamous cell carcinoma (HNSCC) previously treated with checkpoint inhibitor
Cancer Research·2024· 5 cited
Abstract 2654: HPK1 inhibits CD8+ T cell effector gene expression following T cell activation
Cancer Research·2024
Abstract 2485: A combined mregDC and Treg signature associates with antitumor efficacy of CCR4 antagonist tivumecirnon FLX475
Cancer Research·2024· 1 cited
Clinical and molecular effects of oral <scp>CCR4</scp> antagonist <scp>RPT193</scp> in atopic dermatitis: A Phase 1 study
Allergy·2023· 24 citedOpen Access
146 Treatment with the oral CCR4 antagonist RPT193 results in meaningful changes in cutaneous biomarkers detected by transcriptomic profiling of tape strips
Journal of Investigative Dermatology·2023Open Access
704 Biological activity of FLX475, an oral CCR4 antagonist, as monotherapy and in combination with pembrolizumab in advanced cancer
Regular and Young Investigator Award Abstracts·2023· 1 citedOpen Access
629-C Phase 2 safety and efficacy of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with non-small cell lung cancer not previously treated with checkpoint inhibitor
2023· 2 citedOpen Access
Clinical and biological activity of FLX475, an oral CCR4 antagonist, in advanced cancer.
Journal of Clinical Oncology·2023· 1 cited
Figure S3 from Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Patients with Metastatic Pancreatic Cancer
2023Open Access
Table S1 from Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Patients with Metastatic Pancreatic Cancer
2023Open Access
Figure S5 from Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Patients with Metastatic Pancreatic Cancer
2023Open Access
Figure S1 from Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Patients with Metastatic Pancreatic Cancer
2023Open Access
Figure S4 from Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Patients with Metastatic Pancreatic Cancer
2023Open Access
Figure S6 from Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Patients with Metastatic Pancreatic Cancer
2023Open Access
Figure S5 from Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Patients with Metastatic Pancreatic Cancer
2023Open Access
Figure S7 from Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Patients with Metastatic Pancreatic Cancer
2023Open Access
Figure S1 from Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Patients with Metastatic Pancreatic Cancer
2023Open Access
Figure S4 from Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Patients with Metastatic Pancreatic Cancer
2023Open Access
Data from Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Patients with Metastatic Pancreatic Cancer
2023Open Access
page 1 of 10Next →

Frequent Co-authors

Thomas W. Dubensky(22), Peter Lauer(13), Elizabeth M. Jaffee(10), Keith S. Bahjat(9), Lawrence Fong(8), Dung T. Le(8), Aimee Murphy(8), Martin Giedlin(7), Meredith L. Leong(7), Daniel A. Portnoy(6), Weiqun Liu(6), David J. Wustrow(6), Paul D. Kassner(6), Drew M. Pardoll(5), Chan C. Whiting(5), Scott Jacobson(5), Dennis X. Hu(5), Edward E. Lemmens(5), Andrea Wang‐Gillam(4), Vincent J. Picozzi(4)